More than just losing weight
Losing weight saves more than you think
GLP-1 medication and improving your lifestyle doesn't just help with weight loss. You also save on groceries, healthcare costs and sick days. Here's what peer-reviewed research shows.
Groceries
Spending less on food
GLP-1 medication reduces hunger and cravings for unhealthy food. A large-scale study of 150,000 households shows that users consistently spend less on food.
less spent on groceries
less spent on fast food and takeaway
Hristakeva, Liaukonyte & Feler, Journal of Marketing Research, 2025 (n=150,000 households)
Healthcare costs
Lower healthcare costs in the long run
Obesity is one of the most expensive chronic conditions in the Netherlands. Losing weight reduces your healthcare costs and lowers the risk of cardiovascular disease and diabetes.
Average lifetime healthcare costs with a BMI of 35+. The Netherlands has the highest obesity-related healthcare costs in the EU.
Work & productivity
Fewer sick days, more energy
People with obesity are on average 14 days per year sicker than colleagues with a healthy weight. Each sick day costs an employer €250 to €405. Losing weight improves your health, your energy levels and your enjoyment at work.
extra sick days per year with obesity
cost per sick day for employers
Jans et al., TSG, 2007 (n=1.284); Sazas, MKB Servicedesk, Centraal Beheer, 2024
Mental wellbeing
Better in your body, better in your mind
A large study of nearly 100,000 clients found that GLP-1 medication not only helps with weight loss, but also significantly reduces the risk of mental health problems.
Our results
Real numbers from our platform
Collective weight loss, check-ins, lifestyle modules and response times. Transparent and verifiable.
All figures on this page come from peer-reviewed scientific research. Individual results may vary. The savings mentioned are based on group averages and are not a personal guarantee. Always consult a doctor for medical advice.
Blog about medical weight loss
Read our articles about medical weight loss, lifestyle, nutrition, medication, obesity, exercise and healthy living.
Ontsteking en obesitas: waar start de vicieuze cirkel?
Een diepgaande blik op de complexe relatie tussen obesitas en chronische ontsteking, hoe ze elkaar versterken, en hoe leefstijl en nieuwe behandelingen zoals GLP-1 medicatie deze cirkel kunnen doorbreken.
Eerste GLP-1 medicijn goedgekeurd voor MASH in Europa
Europa keurt eerste GLP-1 medicijn goed voor MASH-behandeling. Semaglutide (Kayshild) biedt hoop voor miljoenen met leverziekte.
GLP-1 receptoragonisten en hun rol in het verlagen van infectierisico's
Ontdek hoe GLP-1 receptoragonisten niet alleen diabetes behandelen, maar ook het risico op ernstige infecties verlagen. Lees meer over deze veelbelovende bevindingen!